INTRODUCTION
============

Recent studies have revealed a structurally related family of secreted metalloproteinases which degrade extracellular matrix (ECM) components, such as collagens, fibronectin, laminin and proteoglycans with different substrate specificities. Matrix metalloproteinases (MMPs), including collagenase, gelatinase, stromelysin and membrane-type MMP have been implicated in the remodeeing of ECM, including basement membrane^[@b1-kjim-15-3-171-2])^. ECM remodeling is associated with physiological and pathological processes, including wound healing, angiogenesis, hepatic fibrosis and, more notably, tumor invasion and metastasis^[@b2-kjim-15-3-171-2]--[@b6-kjim-15-3-171-2])^.

Hepatic fibrosis is not caused solely by an increase in connective tissue synthesis but is basically the result of an imbalance between enhanced ECM synthesis and diminished or altered ECM breakdown^[@b7-kjim-15-3-171-2]--[@b10-kjim-15-3-171-2])^. An essential step in the process of tumor invasion and metastasis involves the degradation of ECM, including basement membrane.

Most forms of chronic liver disease are associated with the development of hepatic fibrosis and cirrhosis. Hepatocellular carcinoma frequently occurs in hepatitis B or C virus-related chronic hepatitis or cirrhosis. In particular, cirrhosis has been regarded as a high-risk factor for developing hepatocellular carcinoma.

A large body of evidence indicates that MMPs play a crucial role in hepatic fibrosis, and enhanced MMPs activity has been associated with increases in invasive and metastatic potential in many types of human carcinoma, including hepatocellular carcinoma^[@b11-kjim-15-3-171-2]--[@b14-kjim-15-3-171-2])^.

In general, a number of control mechanisms exist to regulate MMPs activity in tissues. These mechanisms operate at different levels, including gene transcription, proenzyme activation and inhibition of activated enzymes. The latter mechanisms are regulated by tissue inhibitors of metalloproteinases (TIMPs), which bind to the catalytic site of the active enzyme as well as to the carboxyl terminus of the proenzyme, thereby inhibiting its activity and preventing its activation^[@b15-kjim-15-3-171-2]--[@b18-kjim-15-3-171-2])^.

TIMPs bind strongly and stoicheometrically to active form of MMPs and inactivate them. TIMP-1 and TIMP-2 also form tight binding complexes with proMMP-9 and proMMP-2, respectively, to inhibit their activation^[@b15-kjim-15-3-171-2]--[@b18-kjim-15-3-171-2])^. The imbalance of MMPs and TIMPs may contribute to the pathogenesis of hepatic fibrosis and tumor invasion and metastasis. Therefore, it is important to understand the role of TIMPs in hepatocellular carcinoma.

We examined localization of both transcripts and protein of TIMP-1 and TIMP-2 in surgical specimen pairs of hepatocellular carcinoma and nontumoral liver using *in situ* hybridization and immunohistochemistry, and compared it with clinicopathological characteristics.

MATERIALS AND METHODS
=====================

1. Tumor specimens
------------------

Formalin-fixed, paraffin-embedded tissue blocks were obtained from 25 patients who underwent surgery for hepatocellular carcinoma at Chonnam National University Hospital from January 1997 to December 1998. All pathologic slides were reviewed and adequate blocks that showed the junction between tumorous and adjacent nontumorous liver tissue were selected.

The study group consisted of 25 patients with hepatocellular carcinoma (19 men and 6 women; age range, 31--69 years; median, 58.0 years). Identified risk factors were as follows: HBV infection (15 patients), HCV infection (7 patients) and alcoholic cirrhosis (3 patients). Tumor size (range, 2--9 cm; median, 4.5 cm) was less than 4.5cm in 16 patients and \>4.5cm in 9 patients.

The grade of tumor differentiation was as follows: well differentiated in 4 patients, moderately differentiated in 12 patients, and poorly differentiated in 9 patients. Tumors were infiltrative in 9 patients and encapsulated in 16 patients. Capsular invasion was present in 5 of the 16 patients with encapsulated tumors, and satellite nodules were present in 10 patients, with vascular invasion detected in 8 patients ([Table 1](#t1-kjim-15-3-171-2){ref-type="table"}).

2. In situ hybridization
------------------------

For in situ hybridization, two biotinylated oligonucleotide probes complementary to TIMP-1 (TGTGGGTGGGGTGGGACACAGGTGC) and TIMP-2 (CCACTTCCTTCTCACTGACCGC) mRNA were synthesized. All *in situ* hybridization experiments were carried out using manual capillary action technology on the Micro-Probe staining system (Fisher Scientific, Pittsburgh, PA) with the modified one-hour method of Park et al^[@b19-kjim-15-3-171-2])^. Briefly, the slides were rapidly deparaffinized, cleared and rehydrated. The tissues were then digested with pepsin (Sigma, St. Louis, MO) at 2 mg/mL for 1 minute at 110°C. The probe was applied to the slides and the tissues were heated at 110°C for 10 minutes to denature any secondary mRNA structures. The hybridization of the probe and mRNA target was performed by exposing the slides to a microwave oven in which the temperature was gradually decreased from 110°C to 45°C (110°C for 1 min, 95°C for 7 min, 85°C for 7 min, 65°C for 5 min, 45°C for 20 minutes, respectively). The biotinylated hybrids were detected with streptavidin-horseradish peroxidase (Zymed, SanFrancisco, CA) for 7 minutes at 45°C. After preincubation in 3-amino-9-ethylcarbazole (AEC, Sigma, St. Louis, MO) for 7 minutes at 45°C, the tissues were washed with distilled water. Following the chromogen reaction, the tissues were counterstained with hematoxylin solution (Research Genetics, Huntsville, AL), washed with distilled water, air-dried and cover-slipped with Universal mount (Research Genetics, Huntsville, AL). *In situ* hybridization for negative control was performed with probe diluent in hybridization. To evaluate the degree of TIMP-1 and TIMP-2 mRNA expression in tumor tissue, the staining intensity was divided into the following three groups; 0, negative signal; 1, weak signal; 2, strong signal. Assessment of expression was evaluated by two independent observers without knowledge of the clinical outcomes. Consensus scores were assigned for each case by reviewing the slides with discrepancies in scoring. All sections on which the two observers disagreed were re-evaluated and after discussion there was total agreement on the classification.

3. Immunohistochemistry
-----------------------

All procedures for immunohistochemical staining were done by the Micro-Probe staining system (Fisher Scientific, Pittsburgh, PA) based on capillary action^[@b20-kjim-15-3-171-2])^. Paraffin sections of 4*μ*m in thickness with mounted probe on slides were immunostained with anti-mouse monoclonal antibodies for TIMP-1 and TIMP-2 antigens (NeoMarkers, Union, CA) by the avidin-biotin peroxidase complex method^[@b20-kjim-15-3-171-2])^. Sections were dewaxed using absolute alcohol. Antigen retrieval was performed by microwave for 7 minutes in citrate buffer (2.1g/L monohydrate citric acid in distilled water, pH 6.0). After three washes in universal buffer, the slides were immersed in 0.6% hydrogen peroxide for 5 minutes to block the endogenous peroxidase activity. The primary antibodies, used at concentrations of 1:120, 1:100 respectively, were diluted in phosphate-buffered saline supplemented with 5% normal horse serum and 1% bovine serum albumin and then incubated with tissues overnight at room temperature. The slides were washed in universal buffer and incubated with biotinylated affinity-purified anti-mouse immunoglobulin G (Sigma, St. Louis, MO) for 7 minutes at 45°C. After three washes with universal buffer, streptavidin-alkaline phosphatase detection system (Biomeda, Foster, CA) was applied for 7 minutes. As the final step, the slides were developed for 15 minutes with the enzyme substrate, 3 amino-9-ethyl carbazole (AEC, Sigma, St. Louis, MO), and counterstained with hematoxylin solution for 1 minute (Research Genetics, Huntsville, AL). After dehydration, the tissue was sealed with a universal mount (Research Genetics, Huntsville, AL).

4. Statistical Analysis
-----------------------

Significant bivariate associations were tested for all study variables by *χ*^2^ test and Fisher's exact test. The statistical software program used was Statistical Package for the Social Sciences (SPSS/PC+ 8.0, Chicago, IL, USA). A *p*-value of less than 0.05 was accepted as statistically significant.

RESULTS
=======

1. Expression of TIMP-1 and TIMP-2 mRNA
---------------------------------------

TIMP-1 and TIMP-2 mRNA were detected in all hepatocellular carcinoma cases examined. Hybridization signals for TIMP-1 and TIMP-2 mRNA were detected in tumorous tissue, in nontumorous tissue and in the portions of the tumors adjacent to the capsules. However, a clear difference in TIMP-1 and TIMP-2 mRNA expression was not observed between tumorous tissue, nontumorous tissue and the portions of the tumors adjacent to the capsules. In nontumorous portion, hybridization signals for TIMP-1 and TIMP-2 mRNA were detected in hepatocytes, bile duct cells, sinusoidal lining cells and stromal cells ([Figure 1 A, B](#f1-kjim-15-3-171-2){ref-type="fig"}). The expression of TIMP-1 and TIMP-2 mRNA in tumor cells was located in the cytoplasm and showed a diffuse or granular pattern ([Figure 2 A, B](#f2-kjim-15-3-171-2){ref-type="fig"}). Intensity of expression varied among cases and in different areas of the same tumor. With regard to signal intensity of TIMP-1 mRNA, 12 of the cases were weak and 13 were strong ([Table 2](#t2-kjim-15-3-171-2){ref-type="table"}). With regard to signal intensity of TIMP-2 mRNA, 15 of the cases were weak and 10 were strong ([Table 3](#t3-kjim-15-3-171-2){ref-type="table"}). However, the intensity of TIMP-2 expression was generally weaker than TIMP-1.

2. Expression of TIMP-1 and TIMP-2 protein
------------------------------------------

Immunohistochemical study was also performed for identifying the cellular localization of TIMP-1 and TIMP-2 proteins. In all hepatocellular carcinoma tissues, there was a clear immunoreactivity with TIMP-1 and TIMP-2 antibodies. Expression and location of TIMP-1 and TIMP-2 protein, as indicated by immunostaining, correlated well with in situ hybridization analysis of mRNA transcripts. TIMP-1 and TIMP-2 were expressed in tumor cells and tumor stroma. TIMP-1 and TIMP-2 immunoreactivities in tumor stroma were situated in fibroblasts, leukocytes, endothelial cells and ECM ([Figure 3 A, B](#f3-kjim-15-3-171-2){ref-type="fig"}).

3. Correlation between TIMP-1 and TIMP-2 mRNA expression and clinicopathological parameters
-------------------------------------------------------------------------------------------

We tested the relationships between intensity of TIMP-1 and TIMP-2 mRNA expression in tumorous tissue and the following clinicopathological parameters: tumor size, grade of differentiation, pattern of growth, capsule invasion, presence of satellite nodules, basal liver diseases and vascular invasion. There was no correlation between intensity of TIMP-1 and TIMP-2 mRNA expression in tumorous tissue and all clinicopathological parameters ([Table 2](#t2-kjim-15-3-171-2){ref-type="table"}, [Table 3](#t3-kjim-15-3-171-2){ref-type="table"}).

DISCUSSION
==========

Hepatic fibrosis and cirrhosis are associated with excessive deposition of ECM in a distribution and composition different from the non-fibrotic organ^[@b9-kjim-15-3-171-2],[@b10-kjim-15-3-171-2])^. These alterations relate particularly to an absolute and relative accumulation of collagen types I and III in fibrotic and cirrhotic livers^[@b21-kjim-15-3-171-2])^.

Disordered MMP activity could theoretically contribute to such pathological states as progressive hepatic fibrosis and cirrhosis. Advanced hepatic fibrosis and cirrhosis are generally considered to be irreversible conditions even after removal of the injurious agent. Moreover, the development of cirrhosis is characterized by a diminution of liver MMPs activity, implying that the capacity of the diseased liver to remodel the fibrotic matrix is cortically reduced. In studies undertaken to measure MMPs activity in hepatic fibrosis, a general pattern emerges. Initially there is a reversible phase with active ECM remodelling and detectable MMPs activity. In late disease, fibrosis becomes irreversible and, at this point, MMPs activity falls^[@b22-kjim-15-3-171-2]--[@b25-kjim-15-3-171-2])^.

These changes of MMPs activity operate at different levels and control the synthesis of the proenzyme, the secretion of the proenzyme that requires activation and the presence of the metalloproteinases inhibitors. First, all of them are secreted in latent forms (proenzyme) and must be activated for the express ion of their activities. Second, the metalloproteinase activities are regulated by common metalloproteinase inhibitors secreted from various types of cells, such as connective tissue cells, vascular endothelial cells and tumor cells.

Our study showed that, in nontumorous portion with either chronic hepatitis or cirrhosis, expression of TIMP-1 and TIMP-2 were detected in many cell types, including hepatocytes, bile duct cells, sinusoidal lining cells and stromal cells. These results suggest that TIMP-1 and TIMP-2 might be involved in hepatic fibrosis and cirrhosis. Previous reports demonstrated that expression of TIMP-1 and TIMP-2 was increased in human cirrhotic livers in comparison to normal liver^[@b26-kjim-15-3-171-2],[@b27-kjim-15-3-171-2])^. Furthermore, Fukuda et al reported that the expression of TIMP-1 was observed in fibrous tissue, especially in the capsule of hepatocellular carcinoma^[@b28-kjim-15-3-171-2])^. These results may indicate a relationship between the increased expression of TIMP-1 and hepatic fibrosis, as well as a relationship between such increased expression and the hepatocellular carcinoma capsule formation.

Iredale et al reported that the cellular distribution of TIMP-1 and TIMP-2 appear to be similar, although only TIMP-1 is generally found in large amounts^[@b29-kjim-15-3-171-2])^. Our study also showed that a clear difference in TIMP-1 and TIMP-2 expression was not observed between tumorous tissue, nontumorous tissue and the portions of the tumors adjacent to the capsules, and the intensity of TIMP-2 expression was generally weaker than TIMP-1.

In general, an important step in tumor invasion and metastasis is the proteolytic breakdown of ECM in normal tissue surrounding the tumor. Among proteolytic enzymes, the MMPs are the most critical part of this step.

TIMPs concomitantly secreted into the cellular microenvironment interact with MMPs at several levels to stabilize latent enzymes, inhibit active enzymes and modulate the binding of soluble MMPs to surface-bound MMPs, and thereby control the net MMPs activity. Therefore, TIMPs are critical in regulating ECM degradation and tumor invasion and metastasis. Although some studies suggest a role of TIMPs in preventing tumor invasion, others show a complex relationship between MMPs and TIMPs in which the TIMPs were not shown to prevent tumor invasion^[@b30-kjim-15-3-171-2]--[@b34-kjim-15-3-171-2])^.

This paradoxical result indicates that TIMP-1 and TIMP-2 also exhibit other roles than the inhibition of MMPs, which may affect the malignant potential. Hayakawa et al^[@b35-kjim-15-3-171-2],[@b36-kjim-15-3-171-2])^ reported that TIMP-1 and TIMP-2 molecules have growth promoting activity. However, it remains unclear whether TIMPs stimulate the growth of hepatocellular carcinoma cells. In our study, a clear difference in TIMP-1 and TIMP-2 expression was not observed between tumorous tissue, nontumorous tissue and the portions of the tumors adjacent to the capsules. Also, intensity of TIMP-1 and TIMP-2 mRNA expression did not correlate with variable clinicopathological characteristics. The effect of TIMPs on tumor invasion and metastasis are particularly complex. TIMPs synthesis has been known to be regulated by growth factors and cytokines such as transforming growth factor-*β* 1, interleukin and tumor necrosis factor-α^[@b37-kjim-15-3-171-2],[@b38-kjim-15-3-171-2])^.

The influence of other genes, such as those coding for growth factors and metastasis suppressor and dominant metastasis genes, on the possible modulation of MMP/TIMP, together with possible repercussions for the invasive and metastatic properties of the cancer cell, also needs to be studied in depth.

In summary, expression of TIMP-1 and TIMP-2 was found in tumor cells, hepatocyte, sinusoidal cells, endothelial cells and stromal cells. Expression of TIMP-1 and TIMP-2 was observed in tumorous tissue, in nontumorous tissue and in the portions of the tumors adjacent to the capsules. Expression of TIMP-1 was stronger than that of TIMP-2 and intensity of TIMP-1 and TIMP-2 mRNA expression did not correlate with variable clinicopathological characteristics.

Further investigations for TIMPs' unknown functional role are needed.
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![Detection of TIMP-1 and TIMP-2 mRNA by in situ hybridization in nontumorous portion surrounding hepatocellular carcinoma. Hybridization signals for TIMP-1 and TIMP-2 mRNA are detected in hepatocytes, bile duct cells, sinusoidal lining cells and stromal cells (× 200). (A) TIMP-1, (B) TIMP-2](kjim-15-3-171-2f1){#f1-kjim-15-3-171-2}

![Detection of TIMP-1 and TIMP-2 mRNA by in situ hybridization in hepatocellular carcinoma. The expression of TIMP-1 and TIMP-2 m RNA in tumor cells is located in the cytoplasm and shows a diffuse or granular pattern (× 200). (A) TIMP-1, (B) TIMP-2](kjim-15-3-171-2f2){#f2-kjim-15-3-171-2}

![Immunoreactivity of TIMP-1 and TIMP-2 in hepatocellular carcinoma. The tumor cells express TIMP-1 and TIMP-2 in the cytoplasm. The stromal cells also express TIMP-1 and TIMP-2 (× 200). (A) TIMP-1, (B) TIMP-2](kjim-15-3-171-2f3){#f3-kjim-15-3-171-2}

###### 

Clinicopathological parameters of 25 patients with hepatocellular carcinoma

  Parameters                                                                No. of cases(%)
  ------------------------------------------------------------------------- -----------------
  Age(years)                                                                
   \<58                                                                     12/25(48.0)
   ≥58                                                                      13/25(52.0)
  Sex                                                                       
   Male                                                                     19/25(76.0)
   Female                                                                   6/25(24.0)
  Cause[\*](#tfn1-kjim-15-3-171-2){ref-type="table-fn"}                     
   HBV                                                                      15/25(60.0)
   HCV                                                                      7/25(28.0)
   Alcohol                                                                  3/25(12.0)
  Basal liver disease                                                       
   Cirrhosis                                                                15/25(60.0)
   Chronic hepatitis                                                        10/25(40.0)
  Tumor size (cm)                                                           
   \<4.5                                                                    16/25(64.0)
   ≥4.5                                                                     9/25(36.0)
  Differentiation grade[\*\*](#tfn2-kjim-15-3-171-2){ref-type="table-fn"}   
   WD                                                                       4/25(16.0)
   MD                                                                       12/25(48.0)
   PD                                                                       9/25(36.0)
  Pattern of growth                                                         
   Infiltrative                                                             9/25(36.0)
   Encapsulated                                                             16/25(64.0)
  Capsular invasion                                                         
   Absent                                                                   11/16(68.7)
   Present                                                                  5/16(31.3)
  Satellite nodules                                                         
   Absent                                                                   10/25(40.0)
   Present                                                                  15/25(60.0)
  Vascular invasion                                                         
   Absent                                                                   17/25(68.0)
   Present                                                                  8/25(32.0)

HBV; hepatitis B virus, HCV; hepatitis C virus

WD; well differentiated, MD; moderately differentiated, PD; poorly differentiated

###### 

Correlation between expression of TIMP-1 mRNA and clinicopathological parameters of hepatocellular carcinoma

  Clinicopathological Parameters                                          n    Intensity of TIMP-1 mRNA expression   P-value   
  ----------------------------------------------------------------------- ---- ------------------------------------- --------- -------
  Age(years)                                                                                                                   
   \<58                                                                   12   7                                     5         0.320
   ≥58                                                                    13   5                                     8         
  Sex                                                                                                                          
   Male                                                                   19   11                                    8         0.078
   Female                                                                 6    1                                     5         
  Basal liver disease                                                                                                          
   Cirrhosis                                                              15   8                                     7         0.513
   Chronic hepatitis                                                      10   4                                     6         
  Tumor size(cm)                                                                                                               
   \<4.5                                                                  16   9                                     7         0.303
   ≥4.5                                                                   17   7                                     10        
  Differentiation grade[\*](#tfn3-kjim-15-3-171-2){ref-type="table-fn"}                                                        
   WD                                                                     4    2                                     2         0.817
   MD                                                                     12   5                                     7         
   PD                                                                     9    5                                     4         
  Pattern of growth                                                                                                            
   Infiltrative                                                           9    4                                     6         0.973
   Encapsulated                                                           16   7                                     8         
  Capsular invasion                                                                                                            
   Absent                                                                 11   5                                     6         0.590
   Present                                                                5    3                                     2         
  Satellite nodules                                                                                                            
   Absent                                                                 10   4                                     6         0.742
   Present                                                                15   7                                     8         
  Vascular invasion                                                                                                            
   Absent                                                                 17   8                                     9         0.891
   Present                                                                8    4                                     9         

WD; well differentiated, MD; moderately differentiated, PD; poorly differentiated

###### 

Correlation between expression of TIMP-2 mRNA and clinicopathological parameters of hepatocellular carcinoma

  Clinicopathological Parameters                                          n    Intensity of TIMP-2 mRNA expression   *p*-value   
  ----------------------------------------------------------------------- ---- ------------------------------------- ----------- -------
  Age(years)                                                                                                                     
   \<58                                                                   12   5                                     7           0.072
   ≥58                                                                    13   10                                    3           
  Sex                                                                                                                            
   Male                                                                   19   13                                    6           0.126
   Female                                                                 6    2                                     4           
  Basal liver disease                                                                                                            
   Cirrhosis                                                              15   8                                     7           0.513
   Chronic hepatitis                                                      10   7                                     3           
  Tumor size(cm)                                                                                                                 
   \<4.5                                                                  16   9                                     7           0.405
   ≥4.5                                                                   17   7                                     10          
  Differentiation grade[\*](#tfn4-kjim-15-3-171-2){ref-type="table-fn"}                                                          
   WD                                                                     4    3                                     1           0.471
   MD                                                                     12   8                                     4           
  PD                                                                      9    4                                     5           
  Pattern of growth                                                                                                              
   Infiltrative                                                           9    4                                     5           0.234
   Encapsulated                                                           16   11                                    5           
  Capsular invasion                                                                                                              
   Absent                                                                 11   8                                     3           0.611
   Present                                                                5    3                                     2           
  Satellite nodules                                                                                                              
   Absent                                                                 10   5                                     5           0.405
   Present                                                                15   10                                    5           
  Vascular invasion                                                                                                              
   Absent                                                                 17   9                                     8           0.294
   Present                                                                8    6                                     2           

WD; well differentiated, MD; moderately differentiated, PD; poorly differentiated
